Litigation Details for OSI Pharmaceuticals, LLC v. Shilpa Medicare Limited (D. Del. 2018)

OSI Pharmaceuticals, LLC v. Shilpa Medicare Limited (D. Del. 2018)

Docket		Date Filed	2018-07-25
Court	District Court, D. Delaware	Date Terminated	2019-02-25
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	6,900,221
Link to Docket	External link to docket

Details for OSI Pharmaceuticals, LLC v. Shilpa Medicare Limited (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-07-25				External link to document
2018-07-25	20		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,900,221 B1. (Attachments: #… 25 February 2019 1:18-cv-01096 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2018-07-25	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,900,221 B1. (nmg) (Entered:… 25 February 2019 1:18-cv-01096 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

OSI Pharmaceuticals v. Shilpa Medicare: Patent Litigation Summary and Generic Entry Analysis

Last updated: August 26, 2026

OSI Pharmaceuticals, LLC sued Shilpa Medicare Limited in the U.S. District Court for the District of Delaware after Shilpa filed an Abbreviated New Drug Application for generic erlotinib hydrochloride tablets. The case, No. 1:18-cv-01096, was an ANDA patent action under the Hatch-Waxman Act. The dispute centered on U.S. Patent No. 6,900,221, an OSI patent covering methods of treating cancer with erlotinib.

The case did not produce a public claim-construction ruling, infringement judgment, or validity decision. The litigation ended through a confidential resolution, and the publicly available docket does not disclose the agreed generic entry date or other material settlement terms.

What drug and patent were involved in OSI Pharmaceuticals v. Shilpa Medicare?

The litigation involved erlotinib hydrochloride tablets, the active ingredient in Tarceva, formerly marketed by OSI Pharmaceuticals and Genentech for certain non-small-cell lung cancer and pancreatic cancer indications.

Item	Detail
Brand drug	Tarceva
Active ingredient	Erlotinib hydrochloride
Dosage form	Oral tablets
Relevant strengths	25 mg, 100 mg, and 150 mg
Innovator	OSI Pharmaceuticals, LLC and related entities
Generic applicant	Shilpa Medicare Limited
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:18-cv-01096
Case type	Hatch-Waxman ANDA patent litigation
Primary asserted patent	U.S. Patent No. 6,900,221
FDA pathway	Abbreviated New Drug Application

OSI filed the case after receiving notice that Shilpa had made a Paragraph IV certification concerning the asserted patent. A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product.

What patent did OSI assert against Shilpa Medicare?

OSI asserted U.S. Patent No. 6,900,221, titled “Methods of Treating Cancer Using [6,7-Bis(2-Methoxyethoxy)-4-(3-Ethynylphenylamino) Quinazoline].” The patented compound is erlotinib.

The patent was directed primarily to therapeutic use rather than a new tablet formulation. Its asserted value came from method-of-treatment claims covering the administration of erlotinib to cancer patients.

Patent	Subject matter	Listed expiration
U.S. Patent No. 6,900,221	Methods of treating cancer with erlotinib	November 24, 2020

The patent was issued in May 2005. Its term was calculated from an earlier effective U.S. filing date, subject to statutory patent-term adjustments and any applicable pediatric extension. FDA Orange Book records identify the patent as an erlotinib patent covering method-of-use claims.

The earlier core compound patent, U.S. Patent No. 5,747,498, expired before the Shilpa case was filed. That expiration reduced the dispute to later method-of-use protection and any non-patent regulatory barriers.

What were the likely infringement issues in the Shilpa Medicare case?

The case was triggered by Shilpa’s Paragraph IV certification. OSI’s infringement theory likely depended on whether Shilpa’s ANDA labeling would induce infringement of the asserted treatment methods.

In ANDA litigation, the proposed generic label is central. A generic applicant generally seeks approval for the same strengths and conditions of use as the reference-listed drug, subject to any permissible labeling carve-outs. If the proposed labeling instructs physicians to use erlotinib for an indication covered by the patent, the innovator can argue that approval would constitute an artificial act of infringement under 35 U.S.C. § 271(e)(2).

The principal legal issues would have included:

1. Whether Shilpa’s proposed label included a patented indication.
2. Whether the asserted claims covered the proposed use of erlotinib.
3. Whether the patent claims were invalid for anticipation or obviousness.
4. Whether the patent was enforceable.
5. Whether a section viii labeling carve-out could avoid infringement.

The public docket does not show a final decision resolving those issues. There is no publicly reported finding that Shilpa infringed, that the patent was invalid, or that the patent was unenforceable.

When did the erlotinib patent lose exclusivity?

The principal patent barrier expired on November 24, 2020, based on the Orange Book listing for U.S. Patent No. 6,900,221. Any pediatric extension would have to be evaluated separately against the applicable FDA and patent records.

The exclusivity timeline was therefore substantially different from the original Tarceva launch period.

Event	Timing
Tarceva initial FDA approval	November 18, 2004
U.S. Patent No. 5,747,498 expiration	June 2, 2016
OSI v. Shilpa filed	2018
U.S. Patent No. 6,900,221 expiration	November 24, 2020
Expected end of a standard 30-month ANDA stay	Approximately 2021, depending on notice and filing dates
Public resolution of litigation	Confidential settlement or stipulated termination

A 30-month stay can delay FDA approval after a timely patent lawsuit, but it does not extend patent rights. If the stay runs beyond patent expiration, the applicant may still face regulatory timing issues, but the patent itself no longer blocks post-expiration commercialization.

What was the Orange Book status of Tarceva?

The Orange Book listed erlotinib hydrochloride tablets as the reference product for Tarceva. The relevant patent listed for the method-of-use dispute was U.S. Patent No. 6,900,221.

The earlier compound patent had expired by the time OSI sued Shilpa. That left the 6,900,221 patent as the principal remaining Orange Book patent issue in the case.

Formulation patents

The Shilpa litigation is publicly associated with the method-of-use patent rather than a separate erlotinib formulation patent. No public merits record establishes that OSI prevailed on a formulation patent, salt patent, polymorph patent, or tablet-manufacturing patent against Shilpa.

This matters commercially. A method-of-use patent can be avoided through a compliant label carve-out if the patented indication is separable from unpatented indications. A formulation or composition patent generally presents a broader barrier because it can cover the product itself across indications.

Regulatory exclusivity

Tarceva’s principal regulatory exclusivity periods had expired before the Shilpa case. The remaining protection was primarily patent-based. The litigation did not involve biologic exclusivity, biosimilar substitution, or the Biologics Price Competition and Innovation Act.

How did the litigation end?

The public record indicates that the case ended without a reported trial or final merits opinion. The parties resolved the dispute confidentially and filed termination papers in the Delaware action.

Publicly available materials do not disclose:

• The agreed generic launch date.
• Whether Shilpa received a license.
• Whether launch was tied to patent expiration.
• Whether the settlement included a supply, royalty, or authorized-generic arrangement.
• Whether OSI agreed to provide a covenant not to sue.
• Whether Shilpa received an earlier-entry position than other generic applicants.

Because settlement terms were not made public, the case cannot be treated as a judicial validation of the 6,900,221 patent. It also cannot be treated as a finding that Shilpa’s proposed product was non-infringing or that the patent was invalid.

Did Shilpa Medicare receive a Paragraph IV settlement?

The case was a Paragraph IV ANDA action, but the publicly available docket does not disclose the commercial terms of the resolution.

A confidential settlement can take several forms:

• Delayed generic entry before patent expiration.
• Entry on or after patent expiration.
• A license subject to manufacturing or supply conditions.
• A settlement coupled with a permitted label carve-out.
• A commercial agreement that does not grant immediate market access.

No public record identified in the case establishes which structure applied. The absence of disclosed terms limits the ability to calculate Shilpa’s exact launch position relative to other generic applicants.

What litigation risks did Shilpa face?

Shilpa faced the standard risks associated with a Paragraph IV challenge to a method-of-use patent.

Infringement risk

The primary risk was induced infringement based on the proposed prescribing information. If the ANDA label encouraged use covered by the asserted claims, OSI could seek an order delaying approval or preventing commercial marketing until patent expiration.

Validity risk

Method-of-treatment claims could be challenged on obviousness, anticipation, written description, enablement, and other statutory grounds. Erlotinib had extensive prior-art exposure because quinazoline kinase inhibitors and cancer treatment methods were well documented before the patent’s filing date.

Label-carve-out risk

A section viii statement could reduce infringement exposure if the patented indication could be removed without undermining the generic product’s approval for other approved uses. That strategy depends on the exact Orange Book use code and the FDA’s acceptance of the proposed labeling.

Regulatory timing risk

Even if Shilpa prevailed on patent issues, FDA approval timing would depend on the ANDA review, deficiencies, exclusivity held by other applicants, and the status of any 30-month stay.

How strong was OSI’s patent estate for Tarceva?

OSI’s patent estate was strongest during the period when both the compound patent and later method-of-use patents remained in force. By 2018, the estate had materially weakened because the core compound patent had expired.

Estate component	Position in 2018	Commercial effect
Core erlotinib compound patent	Expired	No longer blocked generic composition
Method-of-use patent	Active until November 2020	Could delay or restrict approval
Formulation protection	No public Shilpa merits ruling identified	Limited demonstrated impact in this case
Regulatory exclusivity	Expired	Patent, rather than exclusivity, controlled timing
Biosimilar protection	Not applicable	Erlotinib is a small molecule

The remaining patent had meaningful short-term value because method-of-use claims can support an ANDA lawsuit and delay approval. Its value declined sharply as expiration approached, particularly after the core compound patent expired and generic manufacturers could pursue indications outside the protected use.

Which companies were competing with OSI in generic erlotinib?

Generic erlotinib competition involved multiple ANDA applicants and potential applicants. The relevant competitive landscape included manufacturers seeking approval for tablet strengths corresponding to Tarceva.

The Shilpa case should therefore be analyzed as one proceeding within a broader generic-entry field, not as a standalone exclusivity event. A confidential settlement with one applicant does not establish that other applicants were bound by the same entry restrictions.

Potential competitive variables included:

• Whether another applicant had first-filer status.
• Whether another applicant obtained a 180-day exclusivity period.
• Whether applicants pursued Paragraph IV certifications or section viii statements.
• Whether generic labels carved out the patented indication.
• Whether the FDA approved multiple applicants before or after the 6,900,221 expiration.

The public resolution of OSI v. Shilpa does not establish Shilpa as the first commercial generic entrant.

What was the revenue exposure for Tarceva?

Tarceva was a major oncology product for OSI and Genentech, but sales declined as competing EGFR therapies entered the market and treatment standards changed. By 2018, commercial exposure from the remaining erlotinib patent was lower than during the product’s peak period.

The principal revenue risks were:

1. Generic entry after expiration of the core compound patent.
2. Declining use of erlotinib in lung cancer as newer targeted therapies gained preference.
3. Generic price erosion across the 25 mg, 100 mg, and 150 mg strengths.
4. Potential label carve-outs that allowed generic competition for unpatented indications.
5. The approaching expiration of the 6,900,221 patent.

A confidential settlement may have protected revenue for a limited period, but the public record does not disclose a payment, royalty, or agreed-entry structure that permits a precise valuation.

What manufacturing and intellectual-property barriers remained?

After the compound patent expired, the main barriers shifted from molecule ownership to regulatory execution and commercial scale.

A generic manufacturer still needed to establish:

• Pharmaceutical equivalence to Tarceva.
• Bioequivalence for each proposed strength.
• Stability and manufacturing controls.
• Compliance with current good manufacturing practice requirements.
• Acceptable labeling, including any indication carve-outs.
• Sufficient supply capacity for oncology distribution channels.

These barriers are different from patent exclusivity. They can delay approval or reduce launch effectiveness, but they do not provide the same market control as an enforceable composition patent.

What is the current legal significance of OSI v. Shilpa?

The case is significant as a short-duration Hatch-Waxman dispute over the last major listed erlotinib method-of-use patent. It did not generate a precedential decision on claim scope, induced infringement, obviousness, or section viii carve-outs.

For diligence purposes, the case supports four conclusions:

• The dispute involved a generic erlotinib ANDA.
• U.S. Patent No. 6,900,221 was the central asserted patent.
• The litigation ended without a public merits judgment.
• The patent’s November 2020 expiration substantially limited the long-term commercial value of the dispute.

No biosimilar risk exists because Tarceva is a small-molecule drug. Current competitive risk is generic substitution and erosion of branded erlotinib sales, not biosimilar interchangeability.

Key Takeaways

• OSI sued Shilpa Medicare in Delaware in 2018 over a Paragraph IV ANDA for generic erlotinib hydrochloride tablets.
• The principal asserted patent was U.S. Patent No. 6,900,221.
• The patent covered methods of treating cancer with erlotinib and was listed to expire on November 24, 2020.
• The earlier erlotinib compound patent had already expired when the case was filed.
• The case ended through a confidential resolution without a public infringement, validity, or claim-construction decision.
• The settlement did not publicly establish Shilpa’s launch date, licensing rights, or commercial consideration.
• Formulation, manufacturing, and biosimilar issues did not drive the reported dispute.
• The commercial exposure was concentrated in the period before expiration of the 6,900,221 patent and before broader generic erosion of Tarceva sales.

FAQs

Was OSI Pharmaceuticals v. Shilpa Medicare a Tarceva patent lawsuit?

Yes. The action concerned generic erlotinib hydrochloride tablets, the active ingredient in Tarceva, and was brought under the Hatch-Waxman ANDA litigation framework.

Did Shilpa Medicare invalidate U.S. Patent No. 6,900,221?

No public decision in the case invalidated the patent. The litigation ended without a reported merits judgment.

Did Shilpa Medicare launch generic erlotinib before November 2020?

The public case record does not disclose a definitive Shilpa launch date or establish that Shilpa launched before the patent’s listed expiration.

Was Tarceva protected by a biologic patent or biosimilar exclusivity?

No. Erlotinib is a small-molecule active ingredient regulated through the ANDA pathway. Generic, not biosimilar, competition applies.

Did the case create binding precedent for method-of-use patent litigation?

No. The case ended without a reported judicial opinion establishing binding precedent on the asserted patent or the parties’ infringement positions.

References

1. U.S. District Court for the District of Delaware. (2018). OSI Pharmaceuticals, LLC v. Shilpa Medicare Limited, No. 1:18-cv-01096, docket materials.

2. U.S. Patent and Trademark Office. (2005). U.S. Patent No. 6,900,221: Methods of treating cancer using [6,7-bis(2-methoxyethoxy)-4-(3-ethynylphenylamino) quinazoline].

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book).

4. U.S. Food and Drug Administration. (2016). Tarceva (erlotinib) prescribing information.

5. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs, Tarceva and erlotinib hydrochloride tablets.